Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS9 | O00182 | 1/20 | 0.39 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.39 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 11/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SELP | P16109 | 3/20 | 0.35 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20226171 | 1.00 | LGALS9 (0.39) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL18650712 | 0.99 | PTPN1 (0.39) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL18650683 | 0.91 | PTPN1 (0.44) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL20226177 | 0.91 | PTPN1 (0.44) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL18650701 | 0.90 | PTPN1 (0.46) | PTPN1MEN1USP2POLBKMT2A | |
| SCHEMBL18650717 | 0.89 | LGALS3 (0.40) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL18650711 | 0.86 | PTPN1 (0.38) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL9880223 | 0.86 | LGALS3 (0.38) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL9880217 | 0.86 | LGALS3 (0.38) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL20257764 | 0.85 | LGALS9 (0.41) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180154014-A1 | BETA-1,6-GLUCAN CETUXIMAB ANTIBODY CONJUGATES | IMMUNEXCITE, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20170081428-A1 | IMMUNOMODULATING BETA-1,6-D-GLUCANS | INNATE BIOTHERAPEUTICS, LLC | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180154014-A1 | BETA-1,6-GLUCAN CETUXIMAB ANTIBODY CONJUGATES | CD47, ERBB3, FUT6 | LGALS9 71/4885LGALS1 6/4885LGALS3 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.